These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30203033)

  • 21. Spontaneous splenic rupture due to rivaroxaban.
    Nagaraja V; Cranney G; Kushwaha V
    Drug Ther Bull; 2018 Nov; 56(11):136-139. PubMed ID: 30355723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry.
    Lambert A; Cordeanu M; Gaertner S; Nouri S; Alt M; Stephan D
    Int J Cardiol; 2015 Jul; 191():265-6. PubMed ID: 25981364
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease.
    Theberge I; Bowdridge J; Forgie MA; Carrier M; Louzada M; Siquiera L; Rhodes M; Wells PS
    Thromb Res; 2017 Apr; 152():4-6. PubMed ID: 28192715
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rivaroxaban starter packs on emergency department throughput.
    Ayers GT; D'Amico PhD F; Farrah RM; Klatt PM; Baumgartner MA
    Am J Emerg Med; 2018 Sep; 36(9):1698-1699. PubMed ID: 29429797
    [No Abstract]   [Full Text] [Related]  

  • 35. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
    Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study.
    Lim MS; Indran T; Cummins A; Bennett A; Wood E; Brown S; McQuilten Z; Tran H; Epi MC; Chan NC; Chunilal S
    Semin Thromb Hemost; 2019 Mar; 45(2):187-195. PubMed ID: 30566971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
    Minami K; Kumagai K; Sugai Y; Nakamura K; Naito S; Oshima S
    Intern Med; 2018 Jul; 57(14):2025-2028. PubMed ID: 29526957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
    Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
    Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.